What are the prices of dabrafenib and trametinib in China?

The combination of dabrafenib and trametinib has shown significant efficacy in treating certain types of cancer. Each of these two drugs has a unique mechanism of action, and combining them can produce a more powerful anti-tumor effect.

Dabrafenib is a selectiveBRAF inhibitor that mainly inhibits the kinase activity of BRAF V600 mutant protein. This mutation is found in a variety of cancers and is particularly common in melanoma. Dabrafenib inhibits the proliferation and spread of tumor cells by blocking the signaling of the mutated BRAF protein.

Trametinib is aMEK1/2 inhibitor, which acts on MEK, a key kinase in the MAPK/ERK signaling pathway. This pathway is abnormally activated in a variety of cancers and is closely related to the proliferation and survival of tumor cells. By inhibiting the activity of MEK, trametinib can block this signaling pathway and thereby inhibit tumor growth.

When dabrafenib and trametinib are used together, they can block the MAPK signaling pathway more comprehensively. This combination therapy has shown excellent efficacy in the treatment of unresectable or metastatic melanoma with BRAF V600 mutations. By inhibiting both BRAF and MEK, the two drugs are able to more effectively control the growth and spread of tumor cells.

However, coadministration may also increase the risk of adverse effects. Common adverse reactions may include skin problems (such as rash, itching), gastrointestinal symptoms (such as nausea, vomiting, diarrhea, etc.), fatigue, fever, and abnormal liver function. Therefore, the use of dabrafenib and trametinib combination therapy needs to be under the guidance of a physician and the patient's response should be closely monitored.

Overall, the combination of dabrafenib and trametinib provides an effective means of treating BRAF-mutated cancers. By inhibiting BRAF and MEK simultaneously, these two drugs can produce powerful anti-tumor effects, but they also require close attention and management of possible adverse effects.

Trametinib and dabrafenib are currently on the market in China, and both are included in the national medical insurance reimbursement list, bringing more financial assistance to the majority of patients. In the Chinese market, the original version of dabrafenib is available in two dosage specifications, namely 75 mg × 120 capsules and 50 mg × 120 capsules, which meet the medication needs of different patients. Trametinib is supplied as an original drug with a specification of 2 mg × 30 tablets/box. After being reimbursed by medical insurance, patients can obtain this treatment plan at a price of less than 12,000 yuan.

In addition to China, trametinib and dabrafenib are also launched in many countries and regions around the world. In Türkiye, the specifications of the original version of dabrafenib are75mg × 120 tablets, the price is about 11,000 yuan. At the same time, there are many generic versions of dabrafenib in overseas markets, which are also sold in the specifications of 75 mg × 120 tablets, but the price is more affordable, generally around 2,700 yuan. In addition, the generic version of trametinib is also available overseas, especially in Laos. Many pharmaceutical companies also provide 2 mg × 30 tablets at a price of only about 1,900 yuan, providing patients with more choices and economical options.